Leerink Partners Initiates Coverage on ANI Pharmaceuticals (NASDAQ:ANIP)

Leerink Partners started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research report issued to clients and investors on Wednesday, Briefing.com reports. The brokerage set an “outperform” rating and a $104.00 price target on the specialty pharmaceutical company’s stock. Leerink Partners’ target price would indicate a potential upside of 48.08% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group cut their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Guggenheim dropped their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $105.57.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $70.23 on Wednesday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals has a one year low of $70.15 and a one year high of $99.50. The business’s 50-day moving average price is $78.12 and its two-hundred day moving average price is $78.34. The company has a market capitalization of $1.61 billion, a P/E ratio of 15.14 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts anticipate that ANI Pharmaceuticals will post 7.83 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total value of $401,220.00. Following the completion of the transaction, the chief executive officer owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the completion of the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. This represents a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,925 shares of company stock worth $1,728,385 in the last three months. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. KBC Group NV bought a new position in ANI Pharmaceuticals in the first quarter worth $28,000. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. increased its holdings in ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after buying an additional 249 shares during the period. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at $48,000. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.